Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 16/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 2/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886740 | 0.92 | NPY5R (0.63) | NPY5R | |
| SCHEMBL2887165 | 0.84 | NPY5R (0.61) | NPY5RTNKSTNKS2 | |
| SCHEMBL2886234 | 0.80 | NPY5R (0.53) | NPY5RHTR2B | |
| SCHEMBL2886232 | 0.80 | NPY5R (0.53) | NPY5RHTR2B | |
| SCHEMBL2884466 | 0.79 | NPY5R (0.49) | NPY5RHTR2BTNKSTNKS2HCRTR1 | |
| SCHEMBL2884465 | 0.79 | NPY5R (0.51) | NPY5RHTR2BTNKSTNKS2HCRTR1 | |
| SCHEMBL2889544 | 0.74 | NPY5R (0.42) | NPY5RTNKSTNKS2ADRA1A | |
| SCHEMBL22057351 | 0.72 | TNKS (0.76) | TNKSTNKS2 | |
| SCHEMBL2884993 | 0.71 | NPY5R (0.43) | NPY5RTNKSTNKS2 | |
| SCHEMBL12891787 | 0.71 | HRH3 (0.57) | NPY5RHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060205750-A1 | Novel benzimidazole derivatives | MSD K.K. (JP) | 2006-09-14 | — | — | US | claimed |
| EP-1517908-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-03-30 | — | — | EP | claimed |
| US-20040054177-A1 | Novel benzimidazole derivatives | MSD K.K. (JP) | 2004-03-18 | — | — | US | claimed |
| WO-2004002986-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | WO | claimed |
| EP-3124489-B1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-3124489-A1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | Fibrogen, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2016078-B1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2016-06-15 | — | — | EP | disclosed |
| US-7803807-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7696223-B2 | [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) | FIBROGEN, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7687514-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20100048600-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | MSD K.K. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2016078-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080004309-A1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-01-03 | — | — | US | disclosed |
| WO-2007115315-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20060205750-A1 | Novel benzimidazole derivatives | MSD K.K. (JP) | 2006-09-14 | — | — | US | disclosed |
| US-7105526-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2006-09-12 | — | — | US | disclosed |
| US-20040054177-A1 | Novel benzimidazole derivatives | MSD K.K. (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054177-A1 | Novel benzimidazole derivatives | OPRM1, OPRK1, HTR7 | NPY5R 34/4885HTR2B 45/4885TNKS 2871/4885 |
| US-20060205750-A1 | Novel benzimidazole derivatives | NPY4R, NPY5R, NPY1R | NPY5R 2/4885HTR2B 29/4885TNKS 4115/4885 |
| US-20080004309-A1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | NPY5R 2467/4885HTR2B 3514/4885TNKS 650/4885 |
| US-20100048600-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | NPY4R, NPY5R, NPY1R | NPY5R 2/4885HTR2B 29/4885TNKS 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.